Harrow Health, Inc. (HROW)
USD 25.84
(3.34%)
USD 25.84
(3.34%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 130.19 Million USD | 46.95% |
| 2022 | 88.59 Million USD | 22.24% |
| 2021 | 72.47 Million USD | 48.3% |
| 2020 | 48.87 Million USD | -4.48% |
| 2019 | 51.16 Million USD | 23.67% |
| 2018 | 41.37 Million USD | 54.52% |
| 2017 | 26.77 Million USD | 34.26% |
| 2016 | 19.94 Million USD | 105.25% |
| 2015 | 9.71 Million USD | 485.21% |
| 2014 | 1.66 Million USD | 16502.46% |
| 2013 | 10 Thousand USD | -90.0% |
| 2012 | 100 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | 0.0% |
| 2007 | - USD | 0.0% |
| 2006 | - USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 48.93 Million USD | 41.5% |
| 2024 Q1 | 34.58 Million USD | -4.86% |
| 2023 Q2 | 33.47 Million USD | 28.22% |
| 2023 Q1 | 26.1 Million USD | 28.4% |
| 2023 Q3 | 34.26 Million USD | 2.38% |
| 2023 FY | 130.19 Million USD | 46.95% |
| 2023 Q4 | 36.35 Million USD | 6.1% |
| 2022 Q1 | 22.12 Million USD | 9.57% |
| 2022 FY | 88.59 Million USD | 22.24% |
| 2022 Q4 | 20.32 Million USD | -10.93% |
| 2022 Q3 | 22.82 Million USD | -2.14% |
| 2022 Q2 | 23.32 Million USD | 5.44% |
| 2021 Q3 | 18.71 Million USD | 3.18% |
| 2021 FY | 72.47 Million USD | 48.3% |
| 2021 Q1 | 15.44 Million USD | 5.81% |
| 2021 Q2 | 18.13 Million USD | 17.43% |
| 2021 Q4 | 20.18 Million USD | 7.89% |
| 2020 Q1 | 11.81 Million USD | -6.24% |
| 2020 Q3 | 14.39 Million USD | 78.65% |
| 2020 FY | 48.87 Million USD | -4.48% |
| 2020 Q2 | 8.06 Million USD | -31.79% |
| 2020 Q4 | 14.59 Million USD | 1.36% |
| 2019 FY | 51.16 Million USD | 23.67% |
| 2019 Q1 | 12.29 Million USD | 7.96% |
| 2019 Q2 | 13.51 Million USD | 9.98% |
| 2019 Q3 | 12.75 Million USD | -5.63% |
| 2019 Q4 | 12.6 Million USD | -1.18% |
| 2018 Q2 | 10.38 Million USD | 17.13% |
| 2018 Q3 | 10.73 Million USD | 3.42% |
| 2018 Q4 | 11.38 Million USD | 6.01% |
| 2018 Q1 | 8.86 Million USD | 20.83% |
| 2018 FY | 41.37 Million USD | 54.52% |
| 2017 Q4 | 7.33 Million USD | 13.17% |
| 2017 Q3 | 6.48 Million USD | -5.45% |
| 2017 Q2 | 6.85 Million USD | 12.47% |
| 2017 FY | 26.77 Million USD | 34.26% |
| 2017 Q1 | 6.09 Million USD | 5.25% |
| 2016 Q4 | 5.79 Million USD | 19.17% |
| 2016 Q2 | 4.9 Million USD | 12.01% |
| 2016 Q3 | 4.86 Million USD | -0.94% |
| 2016 FY | 19.94 Million USD | 105.25% |
| 2016 Q1 | 4.38 Million USD | 25.06% |
| 2015 Q3 | 2.68 Million USD | 36.4% |
| 2015 Q4 | 3.5 Million USD | 30.56% |
| 2015 FY | 9.71 Million USD | 485.21% |
| 2015 Q1 | 1.56 Million USD | 184.13% |
| 2015 Q2 | 1.96 Million USD | 25.85% |
| 2014 Q2 | 667.7 Thousand USD | 47254.68% |
| 2014 FY | 1.66 Million USD | 16502.46% |
| 2014 Q4 | 550.1 Thousand USD | 24.73% |
| 2014 Q3 | 441.03 Thousand USD | -33.95% |
| 2014 Q1 | 1410.00 USD | -43.6% |
| 2013 Q4 | 2500.00 USD | 0.0% |
| 2013 FY | 10 Thousand USD | -90.0% |
| 2013 Q1 | 2500.00 USD | 0.0% |
| 2013 Q2 | 2500.00 USD | 0.0% |
| 2013 Q3 | 2500.00 USD | 0.0% |
| 2012 Q3 | - USD | 0.0% |
| 2012 Q2 | - USD | -100.0% |
| 2012 FY | 100 Thousand USD | 0.0% |
| 2012 Q1 | 100 Thousand USD | 0.0% |
| 2012 Q4 | - USD | 0.0% |
| 2011 Q2 | - USD | 0.0% |
| 2011 Q1 | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| 2010 Q3 | - USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2010 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | 34.06 Thousand USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2009 Q2 | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q1 | - USD | 0.0% |
| 2008 FY | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | 0.0% |
| 2007 FY | - USD | 0.0% |
| 2007 Q2 | - USD | 0.0% |
| 2007 Q3 | - USD | 0.0% |
| 2007 Q4 | - USD | 0.0% |
| 2007 Q1 | - USD | 0.0% |
| 2006 Q4 | - USD | 0.0% |
| 2006 FY | - USD | 0.0% |
| 2006 Q3 | - USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 116.33 Million USD | -11.913% |
| Theratechnologies Inc. | 81.76 Million USD | -59.23% |
| Safety Shot Inc | 202.67 Thousand USD | -64138.911% |
| Cosmos Health Inc. | 53.37 Million USD | -143.913% |
| Cronos Group Inc. | 88.84 Million USD | -46.546% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 70.593% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 69.942% |
| Universe Pharmaceuticals INC | 32.3 Million USD | -302.965% |
| ProPhase Labs, Inc. | 44.38 Million USD | -193.333% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | -922.324% |
| Dynavax Technologies Corporation | 232.28 Million USD | 43.951% |
| Radius Health, Inc. | 2.88 Billion USD | 95.483% |
| China SXT Pharmaceuticals, Inc. | 1.92 Million USD | -6651.009% |
| Alvotech | 91.43 Million USD | -42.39% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -440.382% |
| Alpha Teknova, Inc. | 36.68 Million USD | -254.904% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 71.964% |
| SCYNEXIS, Inc. | 140.14 Million USD | 7.099% |
| Biofrontera Inc. | 34.07 Million USD | -282.123% |
| DURECT Corporation | 8.54 Million USD | -1423.081% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 78.57% |
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 73.256% |
| OptiNose, Inc. | 70.98 Million USD | -83.404% |
| RedHill Biopharma Ltd. | 6.51 Million USD | -1898.918% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | -157.385% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | -229.165% |
| SIGA Technologies, Inc. | 139.91 Million USD | 6.95% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | -1.506% |
| Shineco, Inc. | 9.8 Million USD | -1228.248% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 87.207% |
| Procaps Group S.A. | 409.92 Million USD | 68.239% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -9899.462% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Viatris Inc. | 15.42 Billion USD | 99.156% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | -440.382% |
| Rockwell Medical, Inc. | 83.61 Million USD | -55.711% |
| Incannex Healthcare Limited | 12 Thousand USD | -1084841.667% |
| Aytu BioPharma, Inc. | 81 Million USD | -60.728% |
| Tilray Brands, Inc. | 788.94 Million USD | 83.498% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 77.029% |
| PetIQ, Inc. | 1.1 Billion USD | 88.185% |
| Silver Spike Investment Corp. | 11.72 Million USD | -1010.66% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 93.101% |
| Journey Medical Corporation | 79.18 Million USD | -64.425% |
| Alimera Sciences, Inc. | 80.75 Million USD | -61.222% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | -2136.076% |
| Assertio Holdings, Inc. | 152.06 Million USD | 14.386% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Embecta Corp. | 1.12 Billion USD | 88.384% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -11995.169% |
| Procaps Group, S.A. | 409.92 Million USD | 68.239% |
| PainReform Ltd. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | -365.59% |
| Hempacco Co., Inc. | 4.04 Million USD | -3118.109% |
| Talphera, Inc. | 651 Thousand USD | -19898.925% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 80.712% |
| Alvotech | 91.43 Million USD | -42.39% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 89.958% |
| Kamada Ltd. | 144.75 Million USD | 10.062% |
| Indivior PLC | 1.09 Billion USD | 88.088% |
| Currenc Group, Inc. | 53.25 Million USD | -144.469% |
| Evoke Pharma, Inc. | 5.18 Million USD | -2413.073% |
| Flora Growth Corp. | 76.07 Million USD | -71.147% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -11995.169% |
| Evolus, Inc. | 202.08 Million USD | 35.575% |
| HUTCHMED (China) Limited | 837.99 Million USD | 84.464% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 79.796% |
| Akanda Corp. | 2.16 Million USD | -5927.309% |